Griseofulvin Suspension
NDC Package 0713-0850-04
Package Information
Griseofulvin suspension is griseofulvin is indicated for the treatment of dermatophyte infections of the skin not adequately treated by topical therapy, hair and nails, namely: Tinea corporis Tinea pedis Tinea cruris Tinea barbae Tinea capitis Tinea unguium when caused by one or more of the following species of fungi: Epidermophyton floccosum Microsporum audouinii Microsporum canis Microsporum gypseum Trichophyton crateriform Trichophyton gallinae Trichophyton interdigitalis Trichophyton megnini Trichophyton mentagrophytes Trichophyton rubrum Trichophyton schoenleini Trichophyton sulphureum Trichophyton tonsurans Trichophyton verrucosumNote: Prior to therapy, a dermatophyte should be identified as responsible for the infection.Prior to initiating treatment, appropriate specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis.Griseofulvin is not effective in the following:Bacterial infections Coccidioidomycosis Candidiasis (Moniliasis) North American Blastomycosis Histoplasmosis Cryptococcosis (Torulosis) Actinomycosis Tinea versicolor Sporotrichosis Nocardiosis Chromoblastomycosis The use of this drug is not justified in minor or trivial dermatophyte infections which will respond to topical agents alone. This formulation utilizes a suspension delivery system. Marketed by Cosette Pharmaceuticals, Inc., this product is identified by NDC 0713-0850 and is authorized under FDA application ANDA065438.
Identification & Billing
- RxCUI: 239238 - griseofulvin 125 MG in 5 mL Oral Suspension
- RxCUI: 239238 - griseofulvin 25 MG/ML Oral Suspension
- RxCUI: 239238 - griseofulvin 125 MG per 5 ML Oral Suspension
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0713 - Cosette Pharmaceuticals, Inc.
- 0713-0850 - Griseofulvin
- 0713-0850-04 - 118 mL in 1 BOTTLE, PLASTIC
- 0713-0850 - Griseofulvin
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0713-0850-04 identifies a specific commercial package of 118 ml in 1 bottle, plastic of Griseofulvin, a human prescription drug labeled by Cosette Pharmaceuticals, Inc.. This suspension is formulated for oral use and contains griseofulvin as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Cosette Pharmaceuticals, Inc. on November 01, 2022. The current certification is valid through December 31, 2026.
How is this Cosette Pharmaceuticals, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00713085004. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 118 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.